Benzinga | Apr 26, 2021 07:06AM EDT

Baudax Bio Highlights Publication Of Phase IIIb Data On Preoperative Administration Of ANJESO In Patients Undergoing Total Knee Arthroplasty (TKA) in Pain Medicine

Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the online publication of data highlighting the safety and efficacy of preoperative ANJESO(r) (meloxicam) injection in patients undergoing unilateral total knee arthroplasty (TKA) when used within a multimodal analgesic regimen, in the peer-reviewed medical journal Pain Medicine. ANJESO is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.